<DOC>
	<DOCNO>NCT01066481</DOCNO>
	<brief_summary>The purpose study demonstrate safety efficacy PF-01913539 treatment patient mild-to-moderate Alzheimer 's Disease . It 6-month study enrol 651 patient Japan , Hong Kong , Korea , Republic China . All patient complete 6-month study eligible receive PF-01913539 open-label extension trial ( B1451031 ) .</brief_summary>
	<brief_title>A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<criteria>MildtoModerate Alzheimer 's disease MMSE score 1024 inclusive Administration antidementia drug include cholinesteraseinhibitors NMDA receptor antagonist within 90 day Complication cause dementia</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>clinical trial</keyword>
	<keyword>memory loss</keyword>
	<keyword>investigational drug</keyword>
	<keyword>neurodegenerative disease</keyword>
	<keyword>dementia</keyword>
</DOC>